Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Chronic Nodular Prurigo : A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction

Pereira, Manuel P ; Zeidler, Claudia ; Wallengren, Joanna LU ; Halvorsen, Jon A ; Weisshaar, Elke ; Garcovich, Simone ; Misery, Laurent ; Brenaut, Emilie ; Şavk, Ekin and Potekaev, Nikolay , et al. (2021) In Acta Dermato-Venereologica 101.
Abstract

Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite... (More)

Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Dermato-Venereologica
volume
101
article number
adv00403
publisher
Medical Journals Limited
external identifiers
  • pmid:33320272
  • scopus:85102211850
ISSN
1651-2057
DOI
10.2340/00015555-3726
language
English
LU publication?
yes
id
b00532f4-56ce-47d3-81a2-04e3ff871130
date added to LUP
2021-01-22 20:46:47
date last changed
2022-05-12 17:53:17
@article{b00532f4-56ce-47d3-81a2-04e3ff871130,
  abstract     = {{<p>Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.</p>}},
  author       = {{Pereira, Manuel P and Zeidler, Claudia and Wallengren, Joanna and Halvorsen, Jon A and Weisshaar, Elke and Garcovich, Simone and Misery, Laurent and Brenaut, Emilie and Şavk, Ekin and Potekaev, Nikolay and Lvov, Andrey and Bobko, Svetlana and Szepietowski, Jacek C and Reich, Adam and Bozek, Agnieszka and Legat, Franz J and Metz, Martin and Streit, Markus and Serra-Baldrich, Esther and Gonçalo, Margarida and Storck, Michael and Nau, Teresa and Hoffmann, Vincent and Steinke, Sabine and Greiwe, Ina and Dugas, Martin and Augustin, Matthias and Ständer, Sonja}},
  issn         = {{1651-2057}},
  language     = {{eng}},
  month        = {{02}},
  publisher    = {{Medical Journals Limited}},
  series       = {{Acta Dermato-Venereologica}},
  title        = {{Chronic Nodular Prurigo : A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction}},
  url          = {{http://dx.doi.org/10.2340/00015555-3726}},
  doi          = {{10.2340/00015555-3726}},
  volume       = {{101}},
  year         = {{2021}},
}